COMP <GO>
GMED vs PEN // EV/EBITDA & P/E VALUATION
Globus Medical Inc. (NYSE) VS. Penumbra Inc. (NYSE) • 15-METRIC TALLY: GMED 8
— PEN 4
▲ EV/EBITDA & P/E VALUATION LEADER: GMED
LAST: $78.05 (-5.86%) • MKT CAP: $11.13B
valuation
17.6x
LAST: $318.95 (-0.94%) • MKT CAP: $12.68B
valuation
52.0x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (GMED VS. PEN)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | GMED | PEN | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 67.40% | 67.10% | +0.30 | GMED | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 8.70% | 10.60% | -1.90 | PEN | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 17.6x | 52.0x | -34.40 | GMED | /valuation <GO> |
| Free Cash Flow Yield | 5.29% | 1.38% | +3.91 | GMED | /fcf-yield <GO> |
| Operating Margin | 16.30% | 13.50% | +2.80 | GMED | /operating-margins <GO> |
| Net Profit Margin | 18.30% | 12.70% | +5.60 | GMED | /net-margins <GO> |
| Revenue Growth (YoY) | 16.70% | 17.50% | -0.80 | PEN | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 10.74 | 21.05 | -10.31 | PEN | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 9/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 59.8 | 51.9 | +7.90 | GMED | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.07 | 0.91 | +0.16 | GMED | /macro-sensitivity <GO> |
| Forward P/E Multiple | 17.4x | 60.0x | -42.60 | GMED | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $11.13B | $12.68B | -$1.55B | PEN | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | GMED REV | PEN REV | GMED GROSS % | PEN GROSS % | GMED FCF | PEN FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $2.94B | $1.40B | 67.4% | 67.1% | $588.8M | $174.9M |
| FY 2024 | $2.52B | $1.19B | 58.9% | 63.2% | $405.2M | $147.3M |
| FY 2023 | $1.57B | $1.06B | — | — | $172.9M | $49.7M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
GMED // BETA 1.07
PEN // BETA 0.91